Cargando…

Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes

Tumor mass dormancy is the key intermediate step between immune surveillance and cancer progression, yet due to its transitory nature it has been difficult to capture and characterize. Little is understood of its prevalence across cancer types and of the mutational background that may favor such a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Wiecek, Anna Julia, Jacobson, Daniel Hadar, Lason, Wojciech, Secrier, Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299471/
https://www.ncbi.nlm.nih.gov/pubmed/34307377
http://dx.doi.org/10.3389/fcell.2021.698659
_version_ 1783726277080907776
author Wiecek, Anna Julia
Jacobson, Daniel Hadar
Lason, Wojciech
Secrier, Maria
author_facet Wiecek, Anna Julia
Jacobson, Daniel Hadar
Lason, Wojciech
Secrier, Maria
author_sort Wiecek, Anna Julia
collection PubMed
description Tumor mass dormancy is the key intermediate step between immune surveillance and cancer progression, yet due to its transitory nature it has been difficult to capture and characterize. Little is understood of its prevalence across cancer types and of the mutational background that may favor such a state. While this balance is finely tuned internally by the equilibrium between cell proliferation and cell death, the main external factors contributing to tumor mass dormancy are immunological and angiogenic. To understand the genomic and cellular context in which tumor mass dormancy may develop, we comprehensively profiled signals of immune and angiogenic dormancy in 9,631 cancers from the Cancer Genome Atlas and linked them to tumor mutagenesis. We find evidence for immunological and angiogenic dormancy-like signals in 16.5% of bulk sequenced tumors, with a frequency of up to 33% in certain tissues. Mutations in the CASP8 and HRAS oncogenes were positively selected in dormant tumors, suggesting an evolutionary pressure for controlling cell growth/apoptosis signals. By surveying the mutational damage patterns left in the genome by known cancer risk factors, we found that aging-induced mutations were relatively depleted in these tumors, while patterns of smoking and defective base excision repair were linked with increased tumor mass dormancy. Furthermore, we identified a link between APOBEC mutagenesis and dormancy, which comes in conjunction with immune exhaustion and may partly depend on the expression of the angiogenesis regulator PLG as well as interferon and chemokine signals. Tumor mass dormancy also appeared to be impaired in hypoxic conditions in the majority of cancers. The microenvironment of dormant cancers was enriched in cytotoxic and regulatory T cells, as expected, but also in macrophages and showed a reduction in inflammatory Th17 signals. Finally, tumor mass dormancy was linked with improved patient survival outcomes. Our analysis sheds light onto the complex interplay between dormancy, exhaustion, APOBEC activity and hypoxia, and sets directions for future mechanistic explorations.
format Online
Article
Text
id pubmed-8299471
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82994712021-07-24 Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes Wiecek, Anna Julia Jacobson, Daniel Hadar Lason, Wojciech Secrier, Maria Front Cell Dev Biol Cell and Developmental Biology Tumor mass dormancy is the key intermediate step between immune surveillance and cancer progression, yet due to its transitory nature it has been difficult to capture and characterize. Little is understood of its prevalence across cancer types and of the mutational background that may favor such a state. While this balance is finely tuned internally by the equilibrium between cell proliferation and cell death, the main external factors contributing to tumor mass dormancy are immunological and angiogenic. To understand the genomic and cellular context in which tumor mass dormancy may develop, we comprehensively profiled signals of immune and angiogenic dormancy in 9,631 cancers from the Cancer Genome Atlas and linked them to tumor mutagenesis. We find evidence for immunological and angiogenic dormancy-like signals in 16.5% of bulk sequenced tumors, with a frequency of up to 33% in certain tissues. Mutations in the CASP8 and HRAS oncogenes were positively selected in dormant tumors, suggesting an evolutionary pressure for controlling cell growth/apoptosis signals. By surveying the mutational damage patterns left in the genome by known cancer risk factors, we found that aging-induced mutations were relatively depleted in these tumors, while patterns of smoking and defective base excision repair were linked with increased tumor mass dormancy. Furthermore, we identified a link between APOBEC mutagenesis and dormancy, which comes in conjunction with immune exhaustion and may partly depend on the expression of the angiogenesis regulator PLG as well as interferon and chemokine signals. Tumor mass dormancy also appeared to be impaired in hypoxic conditions in the majority of cancers. The microenvironment of dormant cancers was enriched in cytotoxic and regulatory T cells, as expected, but also in macrophages and showed a reduction in inflammatory Th17 signals. Finally, tumor mass dormancy was linked with improved patient survival outcomes. Our analysis sheds light onto the complex interplay between dormancy, exhaustion, APOBEC activity and hypoxia, and sets directions for future mechanistic explorations. Frontiers Media S.A. 2021-07-09 /pmc/articles/PMC8299471/ /pubmed/34307377 http://dx.doi.org/10.3389/fcell.2021.698659 Text en Copyright © 2021 Wiecek, Jacobson, Lason and Secrier. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cell and Developmental Biology
Wiecek, Anna Julia
Jacobson, Daniel Hadar
Lason, Wojciech
Secrier, Maria
Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes
title Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes
title_full Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes
title_fullStr Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes
title_full_unstemmed Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes
title_short Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes
title_sort pan-cancer survey of tumor mass dormancy and underlying mutational processes
topic Cell and Developmental Biology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8299471/
https://www.ncbi.nlm.nih.gov/pubmed/34307377
http://dx.doi.org/10.3389/fcell.2021.698659
work_keys_str_mv AT wiecekannajulia pancancersurveyoftumormassdormancyandunderlyingmutationalprocesses
AT jacobsondanielhadar pancancersurveyoftumormassdormancyandunderlyingmutationalprocesses
AT lasonwojciech pancancersurveyoftumormassdormancyandunderlyingmutationalprocesses
AT secriermaria pancancersurveyoftumormassdormancyandunderlyingmutationalprocesses